Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs in oncology and infectious disease, has announced that the first patient has been dosed in the phase 2a portion of its clinical trial for treatment of a variety of selected cancer indications…
